{"id":"mri-contrast-enhancing-preparations","safety":{"commonSideEffects":[{"rate":null,"effect":"Gadolinium retention (with gadolinium-based agents)"},{"rate":null,"effect":"Nephrogenic systemic fibrosis (rare, with gadolinium in renal impairment)"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL6042476","moleculeType":null,"molecularWeight":"393.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"These agents are paramagnetic or superparamagnetic compounds that shorten relaxation times of nearby water protons, creating enhanced signal intensity in MRI images. By distributing to specific anatomical regions or pathological tissues, they improve tissue differentiation and lesion detection compared to non-contrast MRI.","oneSentence":"MRI contrast-enhancing preparations work by accumulating in target tissues and altering local magnetic properties to improve visualization on magnetic resonance imaging scans.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:10.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Enhancement of MRI imaging in diagnostic procedures"}]},"trialDetails":[{"nctId":"NCT07325292","phase":"PHASE3","title":"Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-14","conditions":"Multiple Sclerosis","enrollment":160},{"nctId":"NCT04879628","phase":"PHASE2","title":"Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Multiple Sclerosis","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MRI contrast-enhancing preparations","genericName":"MRI contrast-enhancing preparations","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MRI contrast-enhancing preparations work by accumulating in target tissues and altering local magnetic properties to improve visualization on magnetic resonance imaging scans. Used for Enhancement of MRI imaging in diagnostic procedures.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}